Buy PT-141
Research-grade PT-141 (Bremelanotide) with purity documentation for melanocortin receptor and arousal signaling research
Research Context
PT-141 (Bremelanotide) is an FDA-approved cyclic melanocortin receptor agonist (Vyleesi, approved 2019 for HSDD). It acts through MC3R/MC4R in the CNS to activate dopaminergic arousal pathways, distinct from peripheral-acting PDE5 inhibitors.
Full PT-141 Research Reference →PT-141 Research Supply
>=98% purity by HPLC with batch-specific CoA. Lyophilized powder, 10mg vials.
View Product PageRead Research ReferenceSourcing Guide
What Researchers Look For
PT-141 is a cyclic heptapeptide, and researchers should verify both HPLC purity and the cyclic structure integrity via mass spectrometry. The expected molecular weight is approximately 1025 Da for the cyclic bremelanotide structure. Linear vs cyclic form would represent a fundamentally different compound, making mass spectrometry structural confirmation particularly important. FDA approval of the pharmaceutical form (Vyleesi) provides clinical reference data for the correct structure and mechanism.
Why Spartan Peptides
Spartan Peptides supplies PT-141 as the authentic cyclic peptide structure at a minimum 98% HPLC purity with batch-specific certificate of analysis. The 10mg vial format supports multiple research applications from receptor binding assays to behavioral pharmacology studies. US domestic dispatch ensures rapid receipt for ongoing reproductive biology research programs.
Specifications
| Purity Standard | >=98% purity by HPLC |
| Format | Lyophilized powder, 10mg vials |
| Storage | Store lyophilized at -20 degrees C. Reconstituted, stable 30 days at 4 degrees C. |
| Origin | USA domestic supply |
| Documentation | Batch-specific certificate of analysis |
Sourcing FAQ
Order Research-Grade PT-141
>=98% purity by HPLC. Lyophilized powder, 10mg vials. Batch-specific CoA. Domestic US supply with same-day dispatch before 2 PM EST.
All compounds are strictly for in-vitro research use only and not intended for human consumption.